PMA (premarket approval) supplement for CardioVascular Dynamics' coronary catheter:
This article was originally published in Clinica
Executive Summary
CardioVascular Dynamics has received a premarket approval supplement for its Guardian coronary catheter, part of a range of catheters developed using the company's Focus technology. It allows most of the dilation force during a balloon angioplasty procedure to be focused more directly to the lesion site. The Guardian catheter is made from a softer, polyethylene-blend material which enhances movement of the guidewire. Its distal tip has been elongated to hug the guidewire, allowing the catheter to reach more distal parts of the anatomy. The company expects full marketing of the product in August.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.